Preventing mother-to-child transmission of HBV

Affiliations

¹ Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China.
² Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China. Electronic address: cuifuq@bjmu.edu.cn.

Comment

Qing-Bin Lu et al. Lancet Infect Dis. 2022 Aug.

. 2022 Aug;22(8):1096-1097.

doi: 10.1016/S1473-3099(22)00216-X. Epub 2022 May 25.

¹ Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China.
² Vaccine Research Center, School of Public Health, Peking University, Beijing 100191, China. Electronic address: cuifuq@bjmu.edu.cn.

No abstract available

Conflict of interest statement

We declare no competing interests.

Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial.
Segeral O, Dim B, Durier C, Nhoueng S, Chhim K, Sovann S, Yom S, Vong C, Yin S, Ros B, Ky V, Pech S, Nem B, Hout K, Guillebaud J, Ear E, Caroupaye-Caroupin L, Rekacewicz C, Fernandez L, Laurent D, Yay C, Kim R, Meyer L, Chhun S; Laurence Borand for the ANRS-MIE TA PROHM Study Group. Segeral O, et al. Lancet Infect Dis. 2022 Aug;22(8):1181-1190. doi: 10.1016/S1473-3099(22)00206-7. Epub 2022 May 25. Lancet Infect Dis. 2022. PMID: 35643089 Clinical Trial.